NO20074044L - Meleimidderivater, farmasoytiske preparater og fremgangsmater for behandling av kreft - Google Patents

Meleimidderivater, farmasoytiske preparater og fremgangsmater for behandling av kreft

Info

Publication number
NO20074044L
NO20074044L NO20074044A NO20074044A NO20074044L NO 20074044 L NO20074044 L NO 20074044L NO 20074044 A NO20074044 A NO 20074044A NO 20074044 A NO20074044 A NO 20074044A NO 20074044 L NO20074044 L NO 20074044L
Authority
NO
Norway
Prior art keywords
pyrroloquinolinyl
methods
cancer
meleimide
dione
Prior art date
Application number
NO20074044A
Other languages
English (en)
Other versions
NO332635B1 (no
Inventor
Mark Anthony Ashwell
Jason Hill
Chiang J Li
Magdi M Moussa
Neru Munshi
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36579999&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20074044(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of NO20074044L publication Critical patent/NO20074044L/no
Publication of NO332635B1 publication Critical patent/NO332635B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Den foreliggende oppfinnelse vedrører pyrrolokinolinylpyrrol-2,5-dionforbindelser og pyrrolokinolinylpyrrolidin-2,5-dionforbindelser, og fremgangsmåter for fremstilling av disse forbindelsene. Den foreliggende oppfinnelse vedrører også farmasøytiske preparater som omfatter pyrrolokinolinylpyrrol-2,5-dionforbindelser og pyrrolokinolinylpyrrolidin-2,5-dionforbindelser. Den foreliggende oppfinnelse tilveiebringer fremgangsmåter for behandling av en celleproliferativ forstyrrelse, slik som en kreftsykdom, ved å administrere til et individ som trenger det, en terapeutisk effektiv mengde av en pyrrolokinolinylpyrrol-2,5-dionforbindelse eller pyrrolokinolinylpyrrolidin-2,5-dionforbindelse ifølge den foreliggende oppfinnelse.
NO20074044A 2005-02-09 2007-08-06 Maleimidderivater, anvendelse derav for fremstilling av et medikament for behandling av kreft og farmasoytiske preparater omfattende derivatene NO332635B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65095105P 2005-02-09 2005-02-09
PCT/US2006/004456 WO2006086484A1 (en) 2005-02-09 2006-02-09 Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer

Publications (2)

Publication Number Publication Date
NO20074044L true NO20074044L (no) 2007-10-10
NO332635B1 NO332635B1 (no) 2012-11-26

Family

ID=36579999

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074044A NO332635B1 (no) 2005-02-09 2007-08-06 Maleimidderivater, anvendelse derav for fremstilling av et medikament for behandling av kreft og farmasoytiske preparater omfattende derivatene

Country Status (25)

Country Link
US (5) US7713969B2 (no)
EP (2) EP1846406B9 (no)
JP (1) JP4171061B2 (no)
KR (1) KR100941205B1 (no)
CN (2) CN101133055B (no)
AT (1) ATE486872T1 (no)
AU (1) AU2006213890B2 (no)
BR (1) BRPI0607240A2 (no)
CA (1) CA2599611C (no)
CY (1) CY1111190T1 (no)
DE (1) DE602006017965D1 (no)
DK (1) DK1846406T5 (no)
ES (1) ES2354267T3 (no)
HR (1) HRP20100650T2 (no)
IL (1) IL184951A (no)
MX (1) MX2007009649A (no)
NO (1) NO332635B1 (no)
NZ (1) NZ560225A (no)
PL (1) PL1846406T3 (no)
PT (1) PT1846406E (no)
RS (1) RS51826B (no)
RU (3) RU2409579C2 (no)
SI (1) SI1846406T1 (no)
WO (1) WO2006086484A1 (no)
ZA (1) ZA200706530B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
RS51826B (sr) 2005-02-09 2012-02-29 Arqule Inc. Maleimid derivati, farmaceutske kompozicije i postupak lečenja kancera
US20070021365A1 (en) * 2005-06-21 2007-01-25 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
WO2008030887A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
JP2010513386A (ja) 2006-12-19 2010-04-30 ノバルティス アーゲー キナーゼ阻害剤としてのインドリルマレイミド誘導体
CA2690782C (en) 2007-06-22 2016-02-02 Arqule, Inc. Compositions and methods for treatment of cancer
CA2690799C (en) * 2007-06-22 2015-06-16 Arqule, Inc. Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
CN101801937A (zh) 2007-06-22 2010-08-11 艾科尔公司 喹唑啉酮化合物及其使用方法
CN101677987A (zh) * 2007-06-22 2010-03-24 赛多斯有限责任公司 不含吐温80的多西他赛的增溶制剂
US7960134B1 (en) 2007-08-01 2011-06-14 Arqule, Inc. Kinase inhibition models and their uses
CA2693310C (en) * 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
WO2009051815A1 (en) * 2007-10-19 2009-04-23 Bipar Sciences, Inc. Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
CN102325755B (zh) 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
CA2752232C (en) * 2009-02-12 2016-11-22 Arqule, Inc. A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with a second anti-proliferative agent
US20110207144A1 (en) * 2009-08-21 2011-08-25 Derek Marshall In vitro screening assays
CA2771702A1 (en) 2009-08-21 2011-02-24 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and loxl2
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
JP2013515737A (ja) * 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
WO2011109237A2 (en) * 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap
US8580764B2 (en) 2010-07-01 2013-11-12 Arqule, Inc. Combinational compositions and methods for treatment of cancer
EP2611443A2 (en) 2010-09-01 2013-07-10 ArQule, Inc. Methods for treatment of non-small cell lung cancer
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US8470786B2 (en) 2010-12-23 2013-06-25 Arqule, Inc. Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
KR20140146036A (ko) 2011-07-07 2014-12-24 아르퀼 인코포레이티드 피롤로퀴놀리닐-피롤리딘-2,5-디온 제제 및 이의 제조 및 사용 방법
EP2841069A4 (en) * 2012-04-23 2015-09-02 Arqule Inc HIGHLY PYRROLOCHINOLINYL-PYRROL-2,5-DION AND PYRROLOCHINOLINYL-PYRROLIDIN-2,5-DION AND METHOD FOR THE PRODUCTION THEREOF
CN102757435B (zh) * 2012-06-21 2014-05-28 成都苑东药业有限公司 一种反式-3-吲哚基-4-吲哚并二氮杂卓环庚烷基-2,5-吡咯烷-2,5-二酮化合物及其制备方法
WO2014098000A1 (en) * 2012-12-17 2014-06-26 Daiichi Sankyo Company, Limited Process for preparation of a tricyclic heterocycle
KR20160023686A (ko) 2013-06-26 2016-03-03 다이이찌 산쿄 가부시키가이샤 3 고리성 복소 고리 화합물의 제조 방법
EA201650031A1 (ru) 2014-05-15 2017-06-30 Итеос Терапьютик Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
BR112017019699A2 (pt) 2015-03-17 2018-09-04 Pfizer Inc. derivados substituídos por 3-indol, composições farmacêuticas e métodos para uso
US10544095B2 (en) 2015-08-10 2020-01-28 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use
EP3337340B1 (en) 2015-08-18 2021-10-06 Purecircle Usa Inc. Steviol glycoside solutions
AU2017386417B2 (en) * 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
CN119431372B (zh) * 2025-01-08 2026-07-17 内蒙古金达威药业有限公司 一种吡咯喹啉醌二钠盐的分离纯化方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US650951A (en) 1899-08-09 1900-06-05 Fred Holmes Rees Station-indicator.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CZ280738B6 (cs) 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
US5380746A (en) 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
CA2015996C (en) 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005969A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5360811A (en) * 1990-03-13 1994-11-01 Hoechst-Roussel Pharmaceuticals Incorporated 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
US5292747A (en) 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
US5591842A (en) 1991-11-29 1997-01-07 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
AU3761393A (en) 1992-03-20 1993-10-21 Wellcome Foundation Limited, The Indole derivatives with antiviral activity
US5721230A (en) 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
EP1449529B1 (en) 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
WO1995030682A1 (en) 1994-05-09 1995-11-16 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyprolocarbazole derivative
US7501441B1 (en) * 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5559228A (en) 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
JP3258334B2 (ja) 1996-03-20 2002-02-18 イーライ・リリー・アンド・カンパニー インドリルマレイミドの合成
PE91698A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
EP0825190A1 (en) 1996-08-23 1998-02-25 Eli Lilly And Company Synthesis of bisindolymaleimides
SE9603283D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US5859261A (en) 1997-03-20 1999-01-12 Eli Lilly And Company Synthesis of indolylmaleimides
JP2001515886A (ja) * 1997-09-08 2001-09-25 ジョージタウン・ユニバーシティ Ｐｋｃの置換された２−ピロリジノン活性化剤
TW380295B (en) * 1997-10-18 2000-01-21 United Microelectronics Corp Manufacturing method for DRAM capacitor dielectric
HUP0103381A3 (en) 1998-07-30 2002-07-29 Japan Tobacco Inc Disubstituted maleimide compounds and medicinal utilization thereof and the pharmaceutical compositions containing the same
EP1152002A4 (en) 1999-02-09 2002-04-17 Sagami Chem Res PYRROL DERIVATIVES AND CELL DEATH INHIBITORS
EP1250334B1 (en) 1999-12-16 2004-05-19 Eli Lilly And Company Medicaments useful for the treatment of proliferative diseases
WO2001044247A2 (en) 1999-12-16 2001-06-21 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
WO2001074807A1 (en) 2000-03-30 2001-10-11 Sagami Chemical Research Center Indolylpyrrole derivatives and cell death inhibitors
DE60129222T2 (de) 2000-05-11 2008-03-06 Consejo Superior de Investigaciónes Científicas Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
JP4993834B2 (ja) 2000-06-29 2012-08-08 ノース ショア−ロング アイランド ジューイッシュ ヘルス システム 細胞増殖および血管形成の調節物質、その使用方法および特定方法
EP1470250A2 (en) 2001-07-15 2004-10-27 Keck Graduate Institute Gene expression analysis using nicking agents
CA2473853A1 (en) 2002-01-23 2003-08-14 J. Suzanne Lindsey Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells
ES2276048T3 (es) 2002-03-05 2007-06-16 Eli Lilly And Company Derivados de purina como inhibidores de cinasa.
CA2522299A1 (en) 2003-04-15 2004-10-28 Avalon Pharmaceuticals, Inc Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
WO2005001486A1 (en) 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
US20070020234A1 (en) 2003-07-07 2007-01-25 Vande Woude George F Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
CN1922208A (zh) 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
RS51826B (sr) 2005-02-09 2012-02-29 Arqule Inc. Maleimid derivati, farmaceutske kompozicije i postupak lečenja kancera
CN101189023B (zh) 2005-03-31 2013-01-30 通用医疗公司 监测和调制hgf/hgfr活性
JP2013515737A (ja) * 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法
KR20140146036A (ko) * 2011-07-07 2014-12-24 아르퀼 인코포레이티드 피롤로퀴놀리닐-피롤리딘-2,5-디온 제제 및 이의 제조 및 사용 방법

Also Published As

Publication number Publication date
US20160355515A1 (en) 2016-12-08
CN101941970B (zh) 2013-08-21
SI1846406T1 (sl) 2011-02-28
BRPI0607240A2 (pt) 2009-08-25
RU2007131428A (ru) 2009-02-27
DE602006017965D1 (de) 2010-12-16
AU2006213890A1 (en) 2006-08-17
PT1846406E (pt) 2010-12-10
IL184951A0 (en) 2007-12-03
IL184951A (en) 2011-11-30
NO332635B1 (no) 2012-11-26
CY1111190T1 (el) 2015-06-11
RS51826B (sr) 2012-02-29
CA2599611A1 (en) 2006-08-17
EP2289892A1 (en) 2011-03-02
US9447088B2 (en) 2016-09-20
HK1107816A1 (en) 2008-04-18
RU2409579C2 (ru) 2011-01-20
JP4171061B2 (ja) 2008-10-22
MX2007009649A (es) 2007-11-15
HRP20100650T2 (hr) 2012-02-29
KR100941205B1 (ko) 2010-02-10
KR20070103047A (ko) 2007-10-22
CN101133055B (zh) 2011-05-25
US8377927B2 (en) 2013-02-19
EP1846406B1 (en) 2010-11-03
US20100221251A1 (en) 2010-09-02
RU2015104346A (ru) 2016-08-27
DK1846406T3 (da) 2011-02-14
ZA200706530B (en) 2009-01-28
HRP20100650T1 (hr) 2011-01-31
US20140200199A1 (en) 2014-07-17
PL1846406T3 (pl) 2011-04-29
RU2547148C2 (ru) 2015-04-10
WO2006086484A1 (en) 2006-08-17
DK1846406T5 (da) 2011-10-31
US20130150310A1 (en) 2013-06-13
RU2010135836A (ru) 2012-03-10
ES2354267T3 (es) 2011-03-11
EP2289892B1 (en) 2012-08-22
ATE486872T1 (de) 2010-11-15
NZ560225A (en) 2010-10-29
CA2599611C (en) 2013-07-30
JP2008530026A (ja) 2008-08-07
CN101941970A (zh) 2011-01-12
AU2006213890B2 (en) 2011-07-21
US20060223760A1 (en) 2006-10-05
US8754078B2 (en) 2014-06-17
EP1846406B9 (en) 2012-01-11
CN101133055A (zh) 2008-02-27
US7713969B2 (en) 2010-05-11
EP1846406A1 (en) 2007-10-24

Similar Documents

Publication Publication Date Title
IL184951A0 (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
EA200700501A1 (ru) Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
EP1951729A4 (en) OXYGEN-BOUND PYRIMIDINE DERIVATIVES
LTPA2016016I1 (lt) Azetinidai kaip mek inhibitoriai, skirti proliferacinių ligų gydymui
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
UA107783C2 (en) Isoindoline compounds for use in treating cancer
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
MX2009013815A (es) Compuestos de quinazolinona y metodos de uso para los mismos.
WO2007048002A3 (en) Camptothecin derivatives as chemoradiosensitizing agents
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
ATE522531T1 (de) Indolylpyrrolidine zur behandlung von krebs
ATE538105T1 (de) Substituierte tetrazolverbindungen und ihre verwendung
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
NO20076075L (no) 4-anilino-3-kinolinkarbonitriler for behandling av cancer
WO2006113718A3 (en) Compositions for the treatment of neoplasms
NO20054723L (no) Behandling av proliferative sykdommer med epofilonderivater og straling
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
DE60309926D1 (de) Steroid-verbindungen mit anti-tumoraler wirkung
MY140324A (en) Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ARQULE INC., US